NCT05474729 Minocycline for Chronic Autoimmune Uveitis
| NCT ID | NCT05474729 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Sun Yat-sen University |
| Condition | Minocycline |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2021-12-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 10 participants in total. It began in 2021-12-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Autoimmune uveitis is one kind of non-infectious, sight-threatening, relapsing and severe ocular disease. Approximately 20%-25% autoimmune uveitis patients suffer from the dilemma of blindness for the chronic and persistent inflammatory state in the eyes, which results in continuous destroy in the structure of the eyes and gradually leads to irreversible damage on visual function. However, it shows limiting efficacy of current treatment including glucocorticoids, immunosuppressant and biologics for chronic autoimmune uveitis. Minocycline has been regarded to have anti-apoptosis and immunemodulatory function for decades and it has been illustrated to be beneficial in several neuro-degenerative and neuro-inflammatory diseases. This trial aims to investigate the efficacy and safety of minocycline for chronic autoimmune uveitis with retinal degenerative changes.
Eligibility Criteria
Inclusion Criteria: * Participant diagnosed of autoimmune diseases with visual function damage (decrease of BCVA, loss of retinal structure) * Participant aged from 18-60 years old. * Participant that signed the informed consent document and is able to complete the following visits. Exclusion Criteria: * Participant is allergy to minocycline or tetracyclines. * Participant has no contraindications of minocycline or tetracyclines. * Participant has an abnormal function of liver, heart, kidney and thyroid. * Participant is using glucocorticoids, immunosuppressants or biologics. * Female that is pregnant, breast-feeding or planning to become pregnant. * Participant that is currently using other medications for other diseases.
Contact & Investigator
Dan Liang
PRINCIPAL INVESTIGATOR
Zhongshan Ophthalmic Center, Sun Yat-sen University
Frequently Asked Questions
Who can join the NCT05474729 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Minocycline. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05474729 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05474729 currently recruiting?
Yes, NCT05474729 is actively recruiting participants. Contact the research team at liangdan@gzzoc.com for enrollment information.
Where is the NCT05474729 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT05474729 clinical trial?
NCT05474729 is sponsored by Sun Yat-sen University. The principal investigator is Dan Liang at Zhongshan Ophthalmic Center, Sun Yat-sen University. The trial plans to enroll 10 participants.